[0 -> 1] 大家早上好 [1 -> 5] 首先感谢大家参加平安健康医疗科技有限公司 [5 -> 8] 2023年中期业绩发布会 [8 -> 10] 我是本次业绩发布会的主持人 [10 -> 13] 平安健康投资者关系部负责人王亦菲 [13 -> 14] Ariel [15 -> 17] 首先请允许我为各位介绍一下 [17 -> 20] 参与本次业绩发布会的公司管理层 [21 -> 24] 他们是平安健康医疗科技有限公司 [24 -> 25] 董事会主席 [25 -> 27] 首席执行官方卫豪先生 [31 -> 35] 平安健康医疗科技有限公司总裁吴军先生 [38 -> 41] 平安健康医疗科技有限公司资深副总裁 [41 -> 44] 暨首席财务官赞洛琪女士 [47 -> 49] 本次会议将由两部分组成 [49 -> 52] 在第一部分中方卫豪先生将介绍公司 [52 -> 56] 2023年上半年的整体经营状况和业绩亮点 [56 -> 59] 之后吴军先生将为各位介绍公司 [59 -> 62] 在2023年上半年业务方面的成功实践 [63 -> 65] 最后赞洛琪女士将回顾公司 [65 -> 68] 在2 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不會就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED 平安健康醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1833） 截至2023年6月30日止六個月期間 未經審計中期業績公告 平安健康醫療科技有限公司（「本公司」）董事會（「董事會」）欣然公佈本公司及其 附屬公司（「本集團」）截至2023年6月30日止六個月期間未經審計中期業績公告。 本公告刊載本公司2023年中期報告（「中期報告」）全文，並符合香港聯合交易所有 限公司（「聯交所」）證券上市規則中有關中期業績初步公告附載的資料之要求。 本公司審計及風險管理委員會已審閱本集團截至2023年6月30日止之六個月期間 中期業績。 本公告將於聯交所網站 www.hkexnews.hk 及本公司網站 www.pagd.net 發佈。截至 2023年6月30日止六個月期間中期報告將適時於上述聯交所及 ...

Business Model and Strategy - Ping An Healthcare has established a sustainable development model focusing on "managed healthcare + family doctor membership + O2O healthcare services" to enhance user experience and shareholder value[10]. - The company has shifted its target audience from individual customers to financially capable corporate clients, aiming to provide comprehensive healthcare services[10]. - The strategic deepening involves expanding product offerings from "healthcare" to "healthcare + wellness" and integrating online and offline services[10]. - Ping An Healthcare aims to become a professional, comprehensive, high-quality, one-stop provider of "healthcare + wellness" management services, with family doctors as key connectors[10]. - The company is facing pressures of comprehensive restructuring in "channels, products, and services" but views this as essential for sustainable development and innovation[10]. - The company emphasizes a "management-style healthcare + family doctor membership system + O2O healthcare service" business model to provide comprehensive healthcare services[14]. Client and User Metrics - In 2022, the company served over 47,000 corporate clients, covering more than 20 million employees, and nearly 228 million individual financial clients as of September 30, 2022[11]. - The company reported a user consultation five-star satisfaction rate exceeding 98% by December 31, 2022[11]. - The number of LTM paying users reached 43 million as of December 31, 2022, representing a growth of 5.3% from 40 million as of June 30, 2022[16]. - The number of B-end cumulative service enterprises increased to 978, a growth of 30.6% from 749[16]. - The company achieved a high renewal rate of nearly 90% among existing large-scale enterprise clients during the reporting period[22]. - The penetration rate of paying users from the Ping An Group's comprehensive financial channel reached approximately 15% of 228 million personal financial users[19]. Financial Performance - The total revenue for the year ended December 31, 2022, was RMB 6,159.8 million, a decrease of 16.0% compared to RMB 7,334.2 million in 2021[15]. - The gross profit margin increased by 4.0 percentage points to 27.3% in 2022, up from 23.3% in 2021[15]. - The net loss for the year decreased by 60.3% to RMB 611.1 million, compared to RMB 1,539.4 million in 2021[15]. - The adjusted net loss for the year was RMB 848.2 million, a decrease of 40.1% from RMB 1,417.2 million in 2021[15]. - Medical services revenue reached RMB 2,547.1 million, up 2.0% from RMB 2,496.0 million in 2021, with a 25.1% increase in the second half of 2022[36]. - Health services revenue declined by 25.3% to RMB 3,612.7 million from RMB 4,838.2 million in 2021, but showed a 13.0% increase in the second half of 2022[38]. Operational Efficiency and Cost Management - The company is actively enhancing profitability through a combination of internal growth and external expansion strategies[12]. - The company focused on enterprise health management products, creating a product system that includes two core products and four customized products[11]. - Sales and marketing expenses for 2022 were RMB 1,105.4 million, a reduction of 37.1% from RMB 1,756.8 million in 2021[40]. - Management expenses decreased by 5.3% to RMB 1,748.4 million in 2022 from RMB 1,846.4 million in 2021, attributed to improved efficiency[41]. - The company has established a comprehensive supplier management quality control system, covering the entire supply chain from entry to exit[27]. Service Network and Partnerships - The company established a "three-to" service network, including "to line," "to store," and "to home/company," enhancing service quality and user experience[11]. - As of December 31, 2022, the company had partnered with over 100,000 offline medical health service institutions, further improving service capabilities[11]. - The company has developed a comprehensive health management solution for medium to large enterprises, focusing on those with sufficient budgets and strong willingness to pay[21]. - The company has built a team of over 49,000 internal and external doctors from 23 departments, maintaining a patient satisfaction rate of over 98%[26]. - The company partnered with over 5,000 hospitals and 224,000 pharmacies, achieving 1-hour delivery in 216 cities and 24/7 delivery in 88 cities as of December 31, 2022[27]. Corporate Governance and Compliance - The company has adopted the corporate governance code and believes it has complied with all applicable provisions during the reporting period, except for the separation of the roles of chairman and CEO[170]. - The board of directors consists of nine members, including two executive directors and three independent non-executive directors[172]. - The independent non-executive directors have confirmed their independence according to the listing rules, ensuring their objectivity during the reporting period[179]. - The company has established mechanisms to ensure the board receives independent views and opinions to promote steady development[175]. - The audit committee reviewed the consolidated financial statements as of December 31, 2022, and confirmed compliance with applicable accounting standards[163]. Employee Relations and Incentives - The group has established a compensation system that includes cash salary, benefits, and long-term incentives, with competitive remuneration based on market conditions and individual performance[57]. - The company’s total number of employees was 2,556 as of December 31, 2022[92]. - The employee incentive plan is effective from December 26, 2014, to December 25, 2024, with approximately 2 years remaining[102]. - The total number of stock options granted under the EIS plan during the year was 73,031,415 shares, with 17,889,932 shares exercised and 1,134,870 shares canceled or expired[112]. - The gender ratio of the company's employees as of December 31, 2022, was 43.9% male and 56.1% female, with ongoing efforts to improve female representation[192]. Social Responsibility and Community Engagement - The company is committed to social responsibility, supporting rural healthcare initiatives and organizing free consultation activities[12]. - The company made charitable donations of approximately RMB 5,000 during the year ending December 31, 2022, compared to RMB 250,000 in 2021[88]. Future Plans and Investments - The company plans to utilize the net proceeds of HKD 7,828 million for further development of its core business before December 31, 2030[78]. - The company has a remaining net amount of HKD 1,674.1 million for business expansion, expected to be used by December 31, 2024[76]. - The company completed acquisitions of 100% stakes in two subsidiaries for a total consideration of approximately RMB 8.08 million and USD 96.86 million in October 2022[56].

[0 -> 2] 大家早上好 [2 -> 5] 感谢各位参加平安健康医疗科技有限公司 [5 -> 8] 2022年年报业绩发布会 [8 -> 10] 我是本次业绩发布会的主持人 [10 -> 13] 平安健康投资者关系部负责人 [13 -> 15] 王以菲 Aria [15 -> 18] 首先请允许我为各位介绍一下 [18 -> 21] 参与本次业绩发布会的公司管理层 [21 -> 24] 他们是平安健康医疗科技有限公司 [24 -> 26] 董事会主席 [26 -> 33] 首席执行官方卫豪先生 [33 -> 42] 平安健康医疗科技有限公司总裁吴军先生 [42 -> 44] 平安健康医疗科技有限公司 [44 -> 48] 资深副总裁兼首席财务官 [48 -> 52] 赞洛琪女士 [52 -> 54] 本次会议将由两部分组成 [54 -> 55] 第一部分中 [55 -> 57] 方卫豪先生将为各位介绍 [57 -> 62] 公司2022年全年的整体经营状况和业绩亮点 [62 -> 65] 之后吴军先生将为各位介绍 [65 -> 69] 公司2022年在业务方面的成功案例实践 [69 -> 72] 最后赞洛 ...

Healthcare Industry Trends - The company emphasizes the importance of providing comprehensive health services and promoting healthy lifestyles as part of China's national health strategy, which is crucial for the 14th Five-Year Plan[13]. - The healthcare industry in China is entering a period of rapid development, driven by increasing public awareness and demand for medical services[13]. - The company has identified a growing need for integrated healthcare management solutions, particularly in the context of the ongoing COVID-19 pandemic, which has highlighted the challenges of traditional healthcare delivery[13]. - According to a report by Mercer, 33% of surveyed companies in China had established health strategy plans by 2020, with nearly 80% planning to increase health management expenditures in 2020-2021[14]. - The company aims to contribute to the "Healthy China 2030" initiative by enhancing national health literacy and promoting integrated healthcare services[13]. Financial Performance - Total revenue for the first half of 2022 was RMB 2,827.9 million, a decrease of 25.9% compared to RMB 3,818.4 million in the first half of 2021[18]. - Gross profit for the first half of 2022 was RMB 773.4 million, down 24.6% from RMB 1,025.2 million in the same period of 2021, with a gross margin of 27.3%, an increase of 0.5 percentage points year-on-year[18]. - The net loss for the first half of 2022 was RMB 425.8 million, a reduction of 51.6% compared to a net loss of RMB 879.3 million in the first half of 2021[18]. - In the first half of 2022, the company's total revenue was RMB 2,827.9 million, a decrease of 19.6% compared to the previous period, primarily due to a decline in health service revenue[21]. - The overall gross margin for the reporting period was 27.3%, an increase of 7.9 percentage points, attributed to a decrease in the proportion of lower-margin business[21]. User Growth and Engagement - The number of registered users increased to 440.7 million as of June 30, 2022, representing a growth of 4.2% from 422.9 million at the end of 2021[19]. - Cumulative consultation volume reached 1,311.5 million, up 3.3% from 1,269.5 million in 2021[19]. - The number of paying users for the last twelve months (LTM) was 40 million, an increase of 4.8% from 39 million in the previous period[20]. - The monthly paying user conversion rate improved to 32.0%, up 7.2 percentage points from 24.8% at the end of 2021[20]. Strategic Initiatives - The company announced its strategic 2.0 initiative in Q4 2021, focusing on high-demand financial channels and corporate clients to bridge the gap between healthcare providers and payers[14]. - The company aims to enhance employee health management as a key component of corporate sustainability and employee welfare, aligning with modern management trends[14]. - The company integrates managed healthcare, family doctor membership systems, and O2O healthcare services into a comprehensive platform[13]. - The company launched the "Health Management +" series of core products, providing comprehensive health management solutions tailored to corporate clients[26]. - The "Health Management +" service includes a dedicated family doctor team, offering 1V1 services that integrate consultation, diagnosis, treatment, and service[26]. Operational Efficiency - The company is committed to addressing the fragmented supply of healthcare services and improving service quality in the market[14]. - The company has implemented a full product lifecycle management system, enhancing product planning, development, and iteration processes[16]. - The company has upgraded its technology architecture to better serve B-end businesses, focusing on data security and privacy protection[17]. - The company achieved a service satisfaction rate exceeding 98% through upgraded services and enhanced efficiency in appointment and management processes[23]. - As of June 30, 2022, the company accumulated nearly 49,000 doctors and health professionals from 20 departments, maintaining a patient satisfaction rate of over 98%[27]. Financial Management and Investments - As of June 30, 2022, total available funds amounted to RMB 13,248.1 million, with cash and cash equivalents at RMB 3,196.1 million[48]. - The company has implemented financial instruments to manage foreign exchange risks, particularly related to fluctuations in the USD/RMB exchange rate[52]. - The company has not repurchased, sold, or redeemed any of its listed securities other than those disclosed for the six months ended June 30, 2022[10]. - The company has established an Audit and Risk Management Committee to oversee financial reporting procedures and internal control systems[68]. - The company reported a significant decrease in sales and marketing expenses, which were RMB 523.5 million, down 52.6% compared to RMB 1,104.4 million in the first half of 2021[41]. Shareholder Information - As of June 30, 2022, the total number of issued shares was 1,118,812,900[1]. - The company repurchased a total of 12,929,300 shares at a total cost of HKD 277,564,150.38 during the six months ended June 30, 2022[2]. - Major shareholders include Anxin with 441 million shares (39.41%) and Hopson Development Holdings Limited with 101,708,800 shares (9.09%)[5]. - The employee incentive plan has unexercised options totaling 20,900,969 shares, equivalent to 1.87% of the company's issued share capital as of June 30, 2022[4]. - The company believes that the market value of its shares is undervalued, reflecting confidence in its future prospects[8]. Compliance and Governance - The board believes that the current management structure effectively safeguards the interests of all shareholders, despite the Chairman also serving as the CEO[70]. - The company has confirmed compliance with the necessary standards regarding directors' securities transactions as of June 30, 2022[69]. - The Audit and Risk Management Committee has reviewed the unaudited interim financial statements for the six months ended June 30, 2022, ensuring compliance with applicable accounting standards[68]. - The company has not recognized any contingent liabilities related to an ongoing litigation case as of June 30, 2022, due to significant uncertainty regarding the outcome[167]. - The interim consolidated financial statements were approved by the board of directors on August 18, 2022[169].

Market Growth and Trends - In 2021, the internet healthcare service usage increased, with nearly 50% of respondents using these services more than the previous year, and over 90% willing to choose online consultations and appointments in the coming year[6]. - The Chinese internet healthcare market is projected to grow rapidly, reaching a scale of 15 trillion yuan by 2025, with penetration increasing from 4.3% in 2020 to 13.2%[6]. - The ongoing pandemic has heightened public health awareness, accelerating the trend towards online medical services[6]. Company Strategy and Positioning - The company aims to enhance social healthcare efficiency by linking quality resources and providing professional guidance to meet diverse user needs[2]. - The company integrates three major models: HMO, family doctor membership system, and O2O medical services, emphasizing user convenience and cost-effectiveness[2]. - The company is positioned as a leading internet healthcare platform in China, bridging the gap between supply and demand in the healthcare industry[2]. - The company’s value proposition focuses on providing healthcare services that save users time, money, and effort[2]. - The company is committed to supporting the "Healthy China 2030" vision by alleviating pressure on social medical resources and meeting individual health needs[10]. Financial Performance - Total revenue for 2021 reached RMB 7,334.2 million, a year-on-year increase of 6.8%, with a gross margin of 23.3%[12]. - The company reported a net loss of RMB 1,539.4 million, a 62.3% increase in losses compared to 2020[12]. - The health service revenue accounted for 68.8% of total revenue, amounting to RMB 5,046.1 million, with a growth rate of 6.3%[12]. - The GMV of the marketplace reached RMB 6,119.9 million, reflecting an 11.8% increase from the previous year[14]. - The company’s annual report is available on its website, providing transparency and accessibility to stakeholders[2]. User Engagement and Satisfaction - The number of registered users increased to 422.9 million, representing a growth of 13.4% compared to 2020[13]. - The cumulative consultation volume reached 1,269.5 million, up 26.4% year-on-year[13]. - Ping An Health achieved over 98% in both consultation and medical record quality ratings, indicating high service quality[8]. - Ping An Health's patient satisfaction gradually improved, with no major medical complaints or disputes reported throughout the year[8]. Compliance and Risk Management - The company completed the ISO 27001 information security management system annual review and obtained ISO 27701 privacy information management system certification during the reporting period[9]. - The company established a mixed internal control management mechanism for its physical medical institutions and pharmacies to ensure stable medical quality and prevent management risks[8]. - The company has established a comprehensive compliance management system to ensure adherence to legal regulations and internal standards, which is crucial for sustainable development[177]. - The company has implemented a clear compliance risk management structure to identify and track compliance risks and regulatory changes[178]. Corporate Governance - The board consists of eight members, including one executive director, four non-executive directors, and three independent non-executive directors[119]. - The company has adopted a corporate governance code and has complied with all applicable provisions, except for the separation of the roles of chairman and CEO[117]. - The audit and risk management committee reviews the effectiveness of the risk management and internal control systems annually[139]. - The company has established clear terms of reference for its committees, defining their powers and responsibilities[126]. Social Responsibility and Sustainability - Ping An Health actively contributed to social responsibility by donating medical supplies and services to impoverished areas, enhancing basic medical service levels[9]. - The company has implemented a poverty alleviation program, providing a "green channel" for related products and combining external donations to achieve targeted poverty alleviation[181]. - The report emphasizes the importance of stakeholder communication and sustainability practices, highlighting the company's commitment to economic, environmental, and social sustainability[167]. - The company has committed to continuous improvement in compliance culture through various training and awareness initiatives[178]. Innovation and Technology - The company has invested 100 million in research and development for new technologies, focusing on improving user experience and operational efficiency[51]. - The company launched an instant audio-video online consultation service in 2021, available 24/7 with a 60-second response time, allowing users to consult with doctors face-to-face[200]. - The company has implemented AI technology to improve online medical service efficiency, with 306 severe disease labels identified across various medical disciplines[199]. Employee Engagement and Development - The company organized over 1,000 training sessions for medical staff throughout the year, covering various aspects of medical regulations and management[8]. - The company has upgraded its employee training system to meet the growth needs of employees and enhance business development[175]. - The employee incentive plan allows for a total of 70 million shares to be granted, with 17,889,932 options unexercised as of December 31, 2021[70]. Future Outlook - The company has set a future outlook with a revenue guidance of 1.8 billion for the next fiscal year, indicating a projected growth of 20%[51]. - New product launches are expected to contribute an additional 200 million in revenue, driven by advancements in technology and user engagement[51]. - The company plans to continue promoting the family doctor membership model to meet high-quality medical health demands[22].

| --- | --- | --- | --- | --- | --- | --- | --- | |-------------------|------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | 平安健康醫療科技有限公司10101 | | | | | | | | | PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED 1010 (於開曼群島註冊成立的有限公司) \| 01000001101010101010101010 2021年中期報告 | | | | | | | | | | | | | | | | | 股份代號：1833.HK | | | | | | | | 南京長江大橋是第一座完全「中國製造」的雙層式公路、鐵 ...